alexa Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept.


Journal of Clinical & Experimental Dermatology Research

Author(s): Fraga NA, Paim Mde F, Follador I, Ramos AN, Rgo VR

Abstract Share this page

Abstract Psoriasis affects 0.12\% to 0.71\% of all children. Erythrodermic psoriasis is an uncommon but serious disorder, occurring in less than 1.5\% of cases. Tumor necrosis factor-alpha blockers (TNF-α) are a new class of drugs used to treat moderate to severe psoriasis refractory to conventional therapies. Etanercept is a TNFα receptor fusion protein, approved by the FDA for treating juvenile rheumatoid arthritis. We present the case of a 7-year-old suffering from plaque psoriasis since 8 months old which evolved into erythroderma refractory to cyclosporine and methotrexate. Patient responded excellently to etanercept, with no adverse side effects.
This article was published in An Bras Dermatol and referenced in Journal of Clinical & Experimental Dermatology Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version